Fundz

Syndeio Biosciences Appoints Aaron Koenig, M.D., as Chief Medical Officer

PRIVATENov 04, 2025

Position

Chief Medical Officer

Company

Syndeio Biosciences

Aaron Koenig
aaron.koenig@syndeio.bio
IndianapolisBiotechnologyHealth CareTherapeuticsresearch

Description

Syndeio Biosciences has appointed Aaron Koenig, M.D., as Chief Medical Officer, bringing over a decade of experience in neuroscience drug development. His appointment is timely as the company prepares to advance its Phase 2 studies of its lead oral synaptic modulator.

Other recent leadership changes in Therapeutics and research

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Syndeio Biosciences, and when

A new leader at Syndeio Biosciences brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Syndeio Biosciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Syndeio Biosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Syndeio Biosciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Syndeio Biosciences

Location

1210 Waterway Blvd

Indianapolis, Indiana, United States

About

Syndeio Biosciences (from the Ancient Greek word “to connect”) is a clinical-stage biotechnology company developing therapies to restore and enhance synaptic health in CNS disorders. The company’s proprietary Boost™ Synapse Pharmacology Platform combines electrophysiology, behavior, and human neuronal network assays to predict clinical outcomes with unprecedented accuracy. Syndeio’s clinical pipeline includes lead asset, zelquistinel, currently in Phase 2 development for major depressive disorder and will soon be entering an industry-first biomarker study in Alzheimer’s disease, and apimostinel, currently in an investigator-led phase 2 study for acute depression. The company is headquartered in Indianapolis, IN with research laboratories in Menlo Park, CA & Evanston, IL focused on advancing the Boost™ Synapse Pharmacology Platform.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Syndeio Biosciences changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Aaron
Likely contact at this company
••••••••@••••••••

See Aaron's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Syndeio Biosciences's next move

Learn about Strategic plan

Syndeio Biosciences changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.